REDEFINE 3 is a study to find out how a new medicine called CagriSema affects heart and blood vessel diseases. Participants will be randomly chosen to receive either CagriSema or a placebo, which is a fake treatment with no effect. The medicine will be given once a week through a small injection in the stomach, thigh, or upper arm. The study will last up to 4.5 years.
To join, you must be at least 55 years old and have a body mass index (BMI) of 25 or more. You should have a history of heart attack, stroke, or other blood vessel problems. If you also have type 2 diabetes, you need to have been diagnosed at least 6 months ago and meet specific health criteria.
Some people cannot join. If you recently had a heart attack or stroke, need certain surgeries, have severe heart failure, or are on certain medications, you might not be eligible.
- Study length: up to 4.5 years
- Weekly injections
- Randomized treatment with equal chance of receiving the study drug or placebo